Effect of aripiprazole combined with risperidone on serum prolactin and glucose lipid metabolism in male patients with schizophrenia
Han SHI,Jing-yuan ZHAO,Yong-feng YANG,Yan ZHANG,Wen-qiang LI,Dai ZHANG,Lu-xian LYU
DOI: https://doi.org/10.7683/xxyxyxb.2018.06.005
2018-01-01
Abstract:Objective To explore the effect of aripiprazole combined with risperidone on serum prolactin and glucolipid metabolism in male patients with schizophrenia. Methods A total of 113 male patients with schizophrenia who were treated with risperidone in the Second Affiliated Hospital of Xinxiang Medical University from October 2016 to May 2017 were select-ed. The patients were randomly divided into observation group and control group. Fifty-nine patients in the control group were given risperidone 4 - 6 mg·d - 1 orally,while fifty-four patients in the observation group were given risperidone 4 - 6 mg·d - 1 combined with aripiprazole 10 mg·d - 1 orally,the course of treatment was 8 weeks. The serum prolactin(PRL)levels were measured before treatment and at 2,4,8 weeks after treatment. Positive and negative syndrome scale(PANSS)was used to eval-uated the psychiatric symptoms in the two groups before treatment and at 4,8 weeks after treatment. The levels of fasting plas-ma glucose(FPG),total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL),high density lipoprotein(HDL), body mass index(BMI)were measured in the two groups before treatment and at 4,8 weeks after treatment. Results A total of 113 patients completed the experiment,with 53 cases in the observation group and 59 cases in the control group. There was no significant difference in the level of PRL,FPG,TC,TG,HDL,LDL and the total score,positive symptom score,negative symptom score,general pathologic score of PANSS and BMI between the two groups before treatment(P > 0. 05). At 2,4,8 weeks after treatment,the level of PRL in the control group was higher than that before treatment(P < 0. 05),and in the obser-vation group it was lower than that before treatment(P < 0. 05). Compared between any two time points,there was significant difference in the PRL level at 2,4,8 weeks after treatment in the two groups(P < 0. 05). Compared with the control group,the level of PRL in the treatment group was significantly lower at 2,4,8 weeks after treatment (P < 0. 01). The total score,positive symptom score,negative symptom score,general pathologic score of PANSS in the two groups at 4,8 weeks after treatment were lower than those before treatment and at 4 weeks after treatment (P < 0. 05). The total score,positive symptom score,negative symptom score,general pathologic score of PANSS in the two groups at 8 weeks after treatment were lower than those at 4 weeks after treatment(P < 0. 05). The total score,negative symptom score,general pathologic score of PANSS in the observation group at 4,8 weeks after treatment were lower than those in the control group(P < 0. 05),but there was no significant difference in the positive symptom score of PANSS between the two groups at 4,8 weeks after treatment(P > 0. 05). There was no significant difference in the level of FPG,TC,TG,HDL,LDL and BMI in the control group at 4,8 weeks after treatment compared with that before treatment(P > 0. 05). There was no significant difference in the level of FPG,TC,TG,HDL,LDL and BMI in the observation group at 4 weeks after treatment compared with that before treatment(P > 0. 05). There was no significant differ-ence in the level of FPG,TC,TG,HDL in the observation group at 8 weeks after treatment compared with that before treatment and at 4 weeks after treatment(P > 0. 05). But the level of LDL and BMI in the observation group at 8 weeks after treatment were lower than those before treatment and at 4 weeks after treatment(P < 0. 05). There was no significant difference in the level of FPG,TC,TG,HDL,LDL and BMI between the observation group and the control group at 4 weeks after treatment(P >0. 05). There was no significant difference in the level of FPG,TC,TG,HDL between the observation group and the control group at 8 weeks after treatment (P > 0. 05). But the level of LDL and BMI in the observation group at 8 weeks after treatment were lower than those in the control group(P < 0. 05). At 8 weeks after treatment,the incidence rate of akathisia,thirst,somno-lence,tremor,nausea and salivation in the control group was 5. 08％,10. 16％,10. 16％,15. 25％,6. 77％,11. 86％,respec-tively;the incidence rate of akathisia,thirst,somnolence,tremor,nausea and salivation in the observation group was 3. 70％, 14. 81％,9. 25％,16. 67％,11. 11％,9. 26％,respectively. There was no significant difference in the incidence rate of akathi-sia,thirst,somnolence,tremor,nausea and salivation between the two groups(χ2 = 0. 207,0. 106,0. 159,0. 326,0. 091,0. 162;P > 0. 05). Conclusion Risperidone combined with aripiprazole in the treatment of male schizophrenia patients is beneficial to reduce the level of serum high PRL induced by risperidone and to improve lipid metabolism.